1. Yogeeswari, P.,Sriram, D., Kumar, A.S.K. et al., Novel N-Spiro substituted compounds. Indian Patent 263536 (Granted on 5th Nov 2014)

2. Yogeeswari, P., Sriram, D., Madhubabu, B., Brahmam, M., Indian Patent Application No. 2945/DEL/2014 (15/10/2014): A Compound for treating inflammatory neuropathic pain and cancer.

3. Saketh, D.V.S., Srikanth, V., Yogeeswari, P., Sriram, D., Indian Patent Application No. 5707/CHE/2014 (13/11/2014): Novel compounds as modulators of AKT.

4. Yogeeswari, P., Sriram, D., Hasitha, S.A., Brahmam, M., Indian Patent Application No. 1763/DEL/2015 (12/06/2015): Cathepsin D inhibitors and compositions thereof for treating breast cancer.

5. Vinay K Nandicoori, Vijay Soni, P. Yogeeswari, D.Sriram, Indian Patent Application No. 3167/DEL/2015 (1/10/2015) M.Tuberculosis GlmU inhibitor

BOOK

Authored book "Medicinal Chemistry" published by Pearson Education

[http://www.pearsoned.co.in/web/books/9788131731444_Medicinal-Chemistry_D--Sriram.aspx]

Chapters in BOOK

1. Book Chapter: P. Yogeeswari and D. Sriram, SUSTAINABILITY IN HIGHER EDUCATION THROUGH BASIC SCIENCE RESEARCH -STRATEGIES FOR CORPORATE BODIES IN PHARMACEUTICALS in Evolving Corporate Education Strategies for Developing Countries: The Role of Universities, Released in Jan 2013 by IGI Global- Officially released by the Hon'ble Minister of Human Resources Development , Government of India, SRI PALLAM RAJU in May 2013

2. Book Chapter: P. Purkayastha, A. Rallapalli, N.L. Bhanu Murthy, A. Malapati, P. Yogeeswari, D. Sriram, EFFECT OF FEATURE SELECTION ON KINASE CLASSIFICATION MODELS in Computational Intelligence in Medicial Informatics, Springer Singapore, 2015.

3. Book Chapter: P. Purkayatha, S. Varanasi, A. Malapati, P. Yogeeswari, D. Sriram, EFFECT OF PHYSIOCHEMICAL PROPERTIES ON CLASSIFICATIONALGORITHMS FOR KINASES FAMILY in Advances in Intelligent Systems and Computing Series, Springer, 2015 (Accepted).

PDB CRYSTAL STRUCTURES WITH OUR INHIBITORS

3ZEI: Structure of the Mycobacterium tuberculosis O-Acetylserine Sulfhydrylase (OASS) CysK1 in complex with a small molecule inhibitor

5AKW: Crystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-one

5AL1: Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1H, 2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one

5AL2: Crystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one

5AL3: Crystal structure of TNKS2 in complex with 2-(2,4-dichlorophenyl)-1- methyl-1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one

5AKU: Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1,2, 3,4-tetrahydroquinazolin-4-one

5AL4: Crystal structure of TNKS2 in complex with 2-(4-methylpiperazin-1-yl)- 3,4,5,6,7,8-hexahydroquinazolin-4-one

5AL5: Crystal structure of TNKS2 in complex with 2-(4-((pyridin-4-yl)methyl) piperazin-1-yl)-3,4,5,6,7,8-hexahydroquinazolin-4-one

5I6D: Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 5 [3-(3-(p-Tolyl)ureido) benzoic acid]

5I7A: Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 1 [3-(3-(3,4-Dichlorophenyl)ureido)benzoic acid]

5I7H: Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 6 [3-(3-(4-Bromophenyl)ureido)benzoic acid]

5I7O: Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 7 [3-(3-(4-Chlorophenyl)ureido)benzoic acid]

5I7R: Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 2 [3-(3-([1,1'-biphenyl]-3-yl)ureido)benzoic acid]

5IW8: Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 4 [5-(3-([1,1'-Biphenyl]-3-yl)ureido)-2-hydroxybenzoic acid]

5IWC : Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 3 [4-(3-([1,1'-Biphenyl]-3-yl)ureido)-2-hydroxybenzoic acid]